A61K 2039/543
Intranasal
Official title: {intranasal}
A61K2039/543 (Intranasal) appears on 949 US grants and 1,577 published applications in this corpus.
Search patents in A61K- Granted patents
- 949
- Published applications
- 1,577
- Assignees
- 791
- Inventors
- 2,974
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 6 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 4 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 3 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 11 | 0 |
| 1998 | 12 | 0 |
| 1999 | 13 | 0 |
| 2000 | 10 | 0 |
| 2001 | 10 | 5 |
| 2002 | 12 | 20 |
| 2003 | 13 | 29 |
| 2004 | 15 | 52 |
| 2005 | 12 | 48 |
| 2006 | 17 | 36 |
| 2007 | 17 | 46 |
| 2008 | 17 | 40 |
| 2009 | 23 | 59 |
| 2010 | 26 | 62 |
| 2011 | 29 | 71 |
| 2012 | 37 | 64 |
| 2013 | 33 | 57 |
| 2014 | 33 | 54 |
| 2015 | 45 | 52 |
| 2016 | 62 | 77 |
| 2017 | 56 | 76 |
| 2018 | 61 | 64 |
| 2019 | 57 | 74 |
| 2020 | 43 | 62 |
| 2021 | 59 | 66 |
| 2022 | 51 | 81 |
| 2023 | 35 | 102 |
| 2024 | 43 | 117 |
| 2025 | 46 | 95 |
| 2026 | 20 | 68 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant protein capable of resisting multiple sclerosis and preparation method and application thereof15 Sep 2026US 12,734,224 B2Institute of Zoology, Guangdong Academy of Sciences
- Compositions and methods for preventing and treating virus infection15 Sep 2026US 12,734,234 B2University of Virginia Patent Foundation
- Vaccine using M2/BM2-deficient influenza vectors8 Sep 2026US 12,728,160 B2FluGen, Inc.
- Method for prevention and treatment of viral disease25 Aug 2026US 12,714,746 B2Morehouse School of Medicine
- Toll-like receptor agonist-nanoparticle vaccine adjuvant28 Jul 2026US 12,691,173 B2The Board of Trustees of the Leland Stanford Junior University
- Mucosal vaccines against tuberculosis8 Oct 2026US 2026/0306604 A1University of Houston System
- Growth hormone targeting polypeptides1 Oct 2026US 2026/0297205 A1The University of Chicago
- A viral vector and a vaccine composition comprising the vector24 Sep 2026US 2026/0284181 A1Rokote Laboratories Finland Oy
- Biological response modifiers for the treatment of subjects with underperforming immune systems and compositions thereof24 Sep 2026US 2026/0284186 A1Center for Genetic Engineering and Biotechnology (Cigb)
- Universal vaccine for african swine fever virus (asfv) infections17 Sep 2026US 2026/0273039 A1DEI Biopharma
Most cited
By later US patents
- Receptor specific transepithelial transport of therapeutics240US 6,485,726 B1Brandeis University · 2002
- Receptor specific transepithelial transport of therapeutics214US 6,030,613 ABrandeis University · 2000
- Receptor specific transepithelial transport of immunogens207US 6,086,875 ABrandeis University · 2000
- Submicron emulsions as vaccine adjuvants129US 5,961,970 APharmos Corporation · 1999
- Method of treating or preventing type 1 diabetes by oral administration of insulin125US 5,763,396 AAutoimmune, Inc. · 1998